



MHRA

10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Prof C Butler
UNIVERSITY OF OXFORD
NUFFIELD DEPARTMENT OF PRIMARY CARE HEALTH SCIENCES,
RADCLIFFE OBSERVATORY QUARTER, WOODSTOCK ROAD
OXFORD
OX2 6GG
UNITED KINGDOM

08/07/2020

Dear Prof C Butler,

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031

Our Reference:	CTA 21584/0426/001-0007
Eudract Number:	2020-001209-22
Product:	Plaquenil-Hydroxychloroquine, Azithromycin, Doxycycline
Protocol number:	PRINCIPLE
Substantial Amendment Code Number:	Substantial Amendment 6, 29 June 2020

NOTICE OF ACCEPTANCE OF AMENDMENT

I am writing to inform you that the Licensing Authority accepts the proposed amendment to your clinical trial authorisation (CTA), received on 07/07/2020.

MEDICAL - Remarks: Remarks:

The following comments are for future consideration / information only and do not affect the approval status of your study. No response is required.

1. The hydroxychloroquine arm of the trial remains suspended until a specific restart is requested and agreed following submission and approval of a substantial amendment. Advice will be sought on the acceptability of any restart from the Commission on Human Medicines.
2. To support a restart of the hydroxychloroquine arm the protocol will need to be amended to address the following outstanding points:
 - a) Provide details of the monitoring of adverse events for all patients using twice weekly routine data extractions from clinical databases in primary care for a subset of participants.
 - b) Provide a stopping rule for the interim analysis to provide a clear mechanism to stop the hydroxychloroquine arm in the event of demonstration of harm at that point.
 - c) Include a requirement that the details and outcome of the first interim analysis will be provided to MHRA in support of continuing the trial at that time

This amendment may therefore be made.



You are reminded that where it is appropriate, the Ethics Committee should also be notified of amendments.

Yours sincerely,

Clinical Trials Unit
MHRA